Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer
作者:Fumiyuki Shirai、Anna Mizutani、Yoko Yashiroda、Takeshi Tsumura、Yuko Kano、Yukiko Muramatsu、Tsubasa Chikada、Hitomi Yuki、Hideaki Niwa、Shin Sato、Kenichi Washizuka、Yasuko Koda、Yui Mazaki、Myung-Kyu Jang、Haruka Yoshida、Akiko Nagamori、Masayuki Okue、Takashi Watanabe、Kouichi Kitamura、Eiki Shitara、Teruki Honma、Takashi Umehara、Mikako Shirouzu、Takehiro Fukami、Hiroyuki Seimiya、Minoru Yoshida、Hiroo Koyama
DOI:10.1021/acs.jmedchem.0c00045
日期:2020.4.23
Tankyrases (TNKS/TNKS2) belong to the poly(ADP-ribose) polymerase family. Inhibition of their enzymatic activities attenuates the Wnt/beta-catenin signaling, which plays an important role in cancer pathogenesis. We previously reported the discovery of RK-287107, a spiroindoline-based, highly selective, potent tankyrase inhibitor. Herein we describe the optimization process of RK-287107 leading to RK-582, which exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered. In addition to the dose-dependent elevation and attenuation of the levels of biomarkers AXIN2 and beta-catenin, respectively, results of the TCF reporter and cell proliferation studies on COLO-320DM are discussed.